Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Renalytix Plc (RENX) Share News

IN BRIEF: Renalytix ends sale process without offer; considers funding

20th Aug 2024 13:15

Renalytix PLC - London-based in vitro diagnostics for kidney disease - Shares fall as Renalytix ends the formal sale process it launched back in March without an offer. Based on its discussions to date, the board doesn't think there is a "realistic prospect" of a takeover offer in the "near term". Renalytix says it is in talks with "key stakeholders" in the company about "a suitable capital structure and funding". Cash runway extends into the fourth quarter of this year based on its cash position of USD4.7 million on June 30. Read More

EARNINGS AND TRADING: Thruvision loss widens but Polarean loss narrows

28th Jun 2024 19:46

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

Shares in Renalytix plunge on possible ADS suspension on Nasdaq

25th Jun 2024 11:43

(Alliance News) - Renalytix PLC on Tuesday said a possible suspension of trading in the company's American depositary shares on Nasdaq could impair its ability to raise capital. Read More

Shares in Renalytix jump as Medicare issues LCD for kidneyintelX.dkd

14th Jun 2024 13:21

(Alliance News) - Renalytix PLC on Friday said Medicare had issued a final local coverage determination for its kidney testing kit, kidneyintelX.dkd. Read More

EXECUTIVE CHANGES: Resolute Mining hires former Acacia exec as chair

29th May 2024 15:45

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and Wednesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Vertu Motors ups dividend as hails record revenue

15th May 2024 18:38

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: Renalytix chief business officer to become president

18th Apr 2024 11:20

Renalytix PLC - London-based diagnostics company focused on the management and testing of kidney disease through its KidneyIntelX platform - Chief Business Officer Howard Doran has been appointed as president, effective April 30. He replaces Thomas McLain, who is stepping down as president on the same date after serving in the role since July 2019. Doran has been business chief since September last year. Read More

UK shareholder meetings calendar - next 7 days

15th Apr 2024 14:09

IN BRIEF: Renalytix announces financing of up to USD4 million

8th Apr 2024 13:34

Renalytix PLC - London-based diagnostics company focused on the management and testing of kidney disease through its KidneyIntelX platform - Announces direct offer of shares at a purchase price equivalent to USD0.75 per NASDAQ American Depositary Share, or USD0.375 per common stock share, to DB Capital Partners Healthcare LP, an investor focused on innovative medical technology. Says the fundraise was conducted by way of a securities purchase agreement, consisting of an initial tranche of 2.7 million shares for USD1.0 million, and an optional subsequent tranche. If the optional tranche is exercised, Renalytix expects the total amount of financing to reach USD4 million. The price of USD0.375 per ordinary share represents a premium of roughly 4.1% to the company's closing price on Friday. Read More

TRADING UPDATES: Horizonte subsidiary hit with debt injunction

14th Mar 2024 18:26

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Renalytix shares sink on heavily discounted placing

12th Mar 2024 13:59

Renalytix PLC - London-based diagnostics company focused on its flagship KidneyIntelX prognostic for patients with kidney disease - Launches placing for around USD10 million, or GBP7.8 million. The placing involves the issue of around 39 million shares in the company at a price of 20 pence each. This represents a roughly 28% discount to the company's Monday closing price of 38.54 pence per share. Renalytix says that issuing more than 20.0 million shares will require shareholder approval, which the company intends to seek at a general meeting, the date and time of which has yet to be confirmed. Read More

IN BRIEF: Renalytix shares up as company commences formal sale process

4th Mar 2024 13:56

Renalytix PLC - London-based diagnostics company, focused on prognosis services for patients with chronic kidney disease - Receives an unsolicited approach from a strategic acquiror which is evaluating a acquisition of the company's entire share capital. Renalytix describes the potential acquiror as a "large and well-capitalised publicly listed strategic diagnostics company". Renalytix has commenced a review of its options, including the sale of the company or its assets, and commenced a formal sale process. Renalytix says it may conclude that its interests are better served by other strategic options, including trading on AIM and Nasdaq as an independent entity, and therefore notes that there is no guarantee of the sale's completion. Read More

Value9,702.53

Change-17.98